The proof will be in the pudding.
The purchase of Flexus for the amount paid is very encouraging, but we must also admit RGBP is not Flexus in personnel, previous investment funding nor objective success. In 2 years, they have objectively had more success than Koos/BMSN/RGBP since its inception.
While my hope is that RGBP will/can turn the corner, I no longer expect it is imminent, since we know quite a bit from the past and delays and PRs that Koos has not been able to get approval or succeed on any deadline or time frame yet.
Last year's spinoff of RGBP was highly anticipated as the defining point of establishing a company with low amount of stocks issued right before the approval and launch of both HemaXellerate I and then dCellVax to follow and we were to launch into dollar land. I actually had high hopes and put most of my investment money on those long term hopes.
Unfortunately, those of us who've been here the past 2 years no the bitter outcome of that. 2/3rds approval when 3/3rds are needed. HemaXellerate I is not near FDA clinical approval. LET IT BE CLEAR - the PRs confirm that Koos and RGBP have not even come to an understanding with the FDA (or the FDA has told RGBP something they can't accomplish) as to the standards and protocol for safety experiments needed for HemaXellerate I to be done and data submitted before FDA can review for clinical approval. MONTHS have passed with the safety protocol still up in the air.
Put 2 years since IND submittal for HemaXellerate I against Flexus 2 years in existence with one drug in actual clinical trials and 2nd drug anticipated to enter clinical trials this year and you will see the difference and reason why RGBP has a long way to go to be valued anywhere near Flexus.
RGBP would easily double from here if we just got confirmation that RGBP was to proceed with safety trials for HemaXellerate. But basically, RGBP ran out of money at the end of last year when HemaX didn't get the expected approval and from what we know, it is no further along today than it was 4 months ago.
Instead, we are now hoping dCellVax goes somewhere, but the RGBP PR released on that in previous months stated that dCellVax was expected to have to go through the same timeframe as HemaXellerate (i.e., no time soon since the experiments for dCellVax where most likely not done in the GLP lab just like HemaX and therefore more experiments will most likely be needed which means more months to wait).
The only real hope I see of this changing is that someone sees real value in the patents and in Wei-Ping Min and in spite of Koos, is willing to make a deal to take over the patents and proceed with the experiments and implement the plan Koos has no money for.
News 
Market Data 
Discover 
